

Thomas R Einarson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9031638/publications.pdf>

Version: 2024-02-01

51
papers

3,664
citations

361296

20
h-index

233338

45
g-index

51
all docs

51
docs citations

51
times ranked

5053
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. <i>Cardiovascular Diabetology</i> , 2018, 17, 83.	2.7	1,198
2	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. <i>Teratology</i> , 2000, 62, 385-392.	1.7	823
3	Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. <i>Clinical Therapeutics</i> , 2007, 29, 918-926.	1.1	214
4	Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 823-827.	0.9	202
5	Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. <i>Value in Health</i> , 2018, 21, 881-890.	0.1	190
6	An Overview of Topical Antifungal Therapy in Dermatomyces. <i>Drugs</i> , 1998, 55, 645-674.	4.9	117
7	Pregnancy outcome following maternal organic solvent exposure: A meta-analysis of epidemiologic studies. , 1998, 34, 288-292.		97
8	Probiotic Safety in Pregnancy: A Systematic Review and Meta-analysis of Randomized Controlled Trials of <i>Lactobacillus</i> , <i>Bifidobacterium</i> , and <i>Saccharomyces</i> spp.. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 542-552.	0.3	84
9	Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2013, 20, e171-83.	1.4	62
10	Does Paroxetine Cause Cardiac Malformations?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2008, 30, 696-701.	0.3	51
11	Hospital-wide Rollout of Antimicrobial Stewardship: A Stepped-Wedge Randomized Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 867-874.	2.9	42
12	Evidence based review of escitalopram in treating major depressive disorder in primary care. <i>International Clinical Psychopharmacology</i> , 2004, 19, 305-310.	0.9	40
13	Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries. <i>International Journal of Clinical Pharmacy</i> , 2001, 23, 76-81.	1.4	25
14	Blood glucose and subsequent cardiovascular disease: update of a meta-analysis. <i>Current Medical Research and Opinion</i> , 2011, 27, 2155-2163.	0.9	25
15	Quality Assessment of Economic Evaluations Published in <i>PharmacoEconomics</i> . <i>PharmacoEconomics</i> , 1997, 12, 685-694.	1.7	24
16	Clinical and Economic Factors in the Treatment of Behavioural and Psychological Symptoms of Dementia. <i>Drugs and Aging</i> , 2001, 18, 527-550.	1.3	24
17	Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. <i>Journal of Medical Economics</i> , 2001, 4, 137-156.	1.0	24
18	Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. <i>Annals of General Psychiatry</i> , 2012, 11, 18.	1.2	23

#	ARTICLE	IF	CITATIONS
19	Utilities for asthma and COPD according to category of severity: a comprehensive literature review. <i>Journal of Medical Economics</i> , 2015, 18, 550-563.	1.0	23
20	Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. <i>Journal of Medical Economics</i> , 2016, 19, 121-130.	1.0	23
21	Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 416-427.	0.7	22
22	Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2017, 33, 331-358.	0.9	22
23	Clinical and Economic Factors in the Treatment of Onychomycosis. <i>Pharmacoeconomics</i> , 1996, 9, 307-320.	1.7	21
24	Comparative effectiveness of interferons in relapsing and remitting multiple sclerosis: a meta-analysis of real-world studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 579-593.	0.9	21
25	Relationship between blood glucose and carotid intima media thickness: A meta-analysis. <i>Cardiovascular Diabetology</i> , 2010, 9, 37.	2.7	20
26	Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada. <i>Pharmacoeconomics</i> , 2001, 19, 551-563.	1.7	19
27	Dose escalation of biologics in Crohn's disease: critical review of observational studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 1433-1449.	0.9	19
28	Patient preferences in severe COPD and asthma: a comprehensive literature review. <i>International Journal of COPD</i> , 2015, 10, 739.	0.9	18
29	Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. <i>Journal of Medical Economics</i> , 2017, 20, 1187-1199.	1.0	17
30	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. <i>Journal of Medical Economics</i> , 2017, 20, 1039-1047.	1.0	17
31	Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. <i>Acta Neuropsychiatrica</i> , 2013, 25, 85-94.	1.0	16
32	Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. <i>Journal of Medical Economics</i> , 2016, 19, 913-921.	1.0	15
33	Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. <i>Journal of Medical Economics</i> , 2013, 16, 1096-1105.	1.0	14
34	An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1322-1330.	0.9	13
35	Prevalence of nausea and vomiting of pregnancy in the USA: a meta analysis. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2013, 20, e163-70.	1.4	13
36	Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. <i>Journal of Medical Economics</i> , 2013, 16, 1089-1095.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomic analysis of topical treatments for tinea infections. <i>International Journal of Dermatology</i> , 1998, 37, 64-71.	0.5	9
38	Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 173.	1.0	9
39	Meta-Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD. <i>Clinical Drug Investigation</i> , 1998, 16, 9-18.	1.1	8
40	A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada. <i>Neurology and Therapy</i> , 2012, 1, 1.	1.4	8
41	Quality and content of abstracts in papers reporting about drug exposures during pregnancy. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2006, 76, 621-628.	1.6	7
42	Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia. <i>Value in Health Regional Issues</i> , 2013, 2, 181-188.	0.5	7
43	Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. <i>Journal of Medical Economics</i> , 2016, 19, 319-355.	1.0	6
44	Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital. <i>Revista De Saude Publica</i> , 2020, 54, 94.	0.7	6
45	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. , 2000, 62, 385.		5
46	The Authority/Pharmacotherapy Care model: an explanatory model of the drug use process in primary care. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 101-117.	1.5	4
47	Validation of an economic model of paliperidone palmitate for chronic schizophrenia. <i>Journal of Medical Economics</i> , 2013, 16, 1267-1274.	1.0	3
48	Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. , 2000, 62, 385.		3
49	Corporate Culture and Change. <i>Journal of Pharmaceutical Marketing and Management</i> , 1992, 6, 33-42.	0.1	0
50	Sales of Brand-Name Products and Generic Competitors Before and After Market Entry of Product Line Extensions in Canada. <i>Journal of Pharmaceutical Marketing and Management</i> , 2006, 17, 19-37.	0.1	0
51	Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital. <i>Revista De Saude Publica</i> , 2020, 54, 94.	0.7	0